Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709549 | 0.87 | GHSR (0.65) | GHSRGAASCN1ASCN2ASCN3A | |
| SCHEMBL1709652 | 0.87 | GHSR (0.57) | GHSRGAAAPPSCN1ASCN2A | |
| SCHEMBL10121984 | 0.86 | GHSR (0.55) | GHSRGAAMCL1SCN1ASCN2A | |
| SCHEMBL10122103 | 0.85 | GHSR (0.65) | GHSRGAASCN1ASCN2ASCN3A | |
| SCHEMBL10121676 | 0.85 | GHSR (0.64) | GHSRGAASCN1ASCN2ASCN3A | |
| SCHEMBL10121682 | 0.85 | GHSR (0.69) | GHSRGAASCN1ASCN2ASCN3A | |
| SCHEMBL10121950 | 0.85 | GHSR (0.64) | GHSRGAASCN1ASCN2ASCN3A | |
| SCHEMBL1709605 | 0.84 | GHSR (0.64) | GHSRGAASCN1ASCN2ASCN3A | |
| SCHEMBL1709677 | 0.84 | GHSR (0.63) | GHSRCNR2GAASCN1ASCN2A | |
| SCHEMBL10121683 | 0.84 | GHSR (0.63) | GHSRGAASCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885KLKB1 2756/4885CNR2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.